Company intelligence / Profile preview

NatureWise Biotech & Medicals Corporation

Taipei, Taipei City, Taiwannaturewise.com.tw ↗

Ownership: Private
Employees: ~32
Development stage: Commercial

Overview

NatureWise has commercialized LipoCol Forte® for hypercholesterolemia and hypertriglyceridemia, which is the first traditional Chinese medicine approved in Taiwan after GCP clinical trials. Its lead oncology asset, NBM-BMX softgel capsules targeting HDAC8, is in Phase 2 clinical trials for neoplasms. The company also develops health supplements based on patented Taiwanese green propolis extract with neurotrophic and anti-diabetic activities

Therapeutic areas: Metabolic DisordersCardiovascularOphthalmologyOncology
Modalities: Small moleculesNatural products (e.g., propolis extracts)
Industry: Biotech

Drug pipeline

1 asset

NBM-BMX

Beyond the preview

Go deeper on NatureWise Biotech & Medicals Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NatureWise Biotech & Medicals Corporation.

Explore the full profile